Matching articles for "midostaurin"

Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)

   
The Medical Letter on Drugs and Therapeutics • October 16, 2023;  (Issue 1687)
The FDA has approved the oral kinase inhibitor quizartinib (Vanflyta – Daiichi Sankyo) for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as...
The FDA has approved the oral kinase inhibitor quizartinib (Vanflyta – Daiichi Sankyo) for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy in adults with FLT3 internal tandem duplication (ITD)-positive, newly-diagnosed acute myeloid leukemia (AML).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e169-70 | Show Full IntroductionHide Full Introduction

In Brief: Midostaurin (Rydapt) for AML and Advanced Systemic Mastocytosis (online only)

   
The Medical Letter on Drugs and Therapeutics • August 14, 2017;  (Issue 1527)
The FDA has approved the oral multikinase inhibitor midostaurin (Rydapt – Novartis) for first-line treatment, in addition to standard chemotherapy, of adults with FLT3 (fms-like tyrosine kinase 3)...
The FDA has approved the oral multikinase inhibitor midostaurin (Rydapt – Novartis) for first-line treatment, in addition to standard chemotherapy, of adults with FLT3 (fms-like tyrosine kinase 3) mutation-positive acute myeloid leukemia (AML). About 30% of patients with AML have FLT3 mutations. Midostaurin is also approved as a single agent for treatment of adults with aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast-cell leukemia. In mastocytosis, midostaurin targets mutant c-KIT, not FLT3.

In a randomized, double-blind trial, 717 adults 18-59 years old with newly diagnosed FLT3-mutated AML were treated with midostaurin (50 mg twice daily on days 8-21 of each 28-day cycle) or placebo in addition to standard chemotherapy (induction therapy with cytarabine and daunorubicin and consolidation therapy with high-dose cytarabine), followed by up to 12 additional maintenance cycles of midostaurin or placebo. More than half of the patients (57%) stopped treatment and underwent hematopoietic stem-cell transplantation during the trial. Median event-free survival was 8.2 months with midostaurin compared to 3.0 months with placebo, a significant difference. Median overall survival after a median follow-up of 59 months was significantly longer with midostaurin than with placebo (hazard ratio 0.78). The 4-year overall survival rate was 51.4% with midostaurin and 44.3% with placebo.1 Common adverse effects reported in the midostaurin plus chemotherapy group at a rate at least 2% higher than in the placebo plus chemotherapy arm included febrile neutropenia (83% vs 81%), nausea (83% vs 70%), vomiting (61% vs 53%), and mucositis (66% vs 62%). There were no differences between the two groups in the rates of severe (≥grade 3) adverse events.

A single-arm, phase 2 study of midostaurin (100 mg twice daily in 4-week continuous cycles) included 89 adults with advanced systemic mastocytosis (16 had mast-cell leukemia) and evidence of organ damage. The overall response rate was 60%, and 45% of patients had a major response (complete resolution of at least one type of mastocytosis-related organ damage). The median duration of response was 24.1 months. Treatment with midostaurin also decreased splenomegaly and bone marrow mastcell burden. Median progression-free survival was 14.1 months and median overall survival was 28.7 months (9.4 months in patients with mast-cell leukemia). The most common adverse effects of midostaurin were nausea, vomiting, and diarrhea. New or worsening grade 3 or 4 neutropenia, anemia, and thrombocytopenia occurred in >20% of patients.2

Rydapt is available in 25-mg capsules. For patients with AML, a 4-week treatment cycle (50 mg twice daily on days 8-21) costs $7495. For patients with advanced systemic mastocytosis, 4 weeks of treatment at 100 mg twice daily costs $29,980.3

  1. RM Stone et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017 Jun 23 (epub).
  2. J Gotlib et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 2016; 374:2530.
  3. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource®Monthly. July 5, 2017. Reprinted with permission by First Databank, Inc. All rights reserved. ©2017. www.fdbhealth.com/policies/drug-pricing-policy.


Download complete U.S. English article

Med Lett Drugs Ther. 2017 Aug 14;59(1527):e140 | Show Full IntroductionHide Full Introduction